Alexander V Ljubimov Selected Research

poly(malic acid)

12/2016	Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
12/2013	Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment.
2/2011	Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.
10/2010	Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected].
1/2006	Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexander V Ljubimov Research Topics

Disease

17	Neoplasms (Cancer) 10/2021 - 10/2003
10	Brain Neoplasms (Brain Tumor) 10/2021 - 01/2006
10	Glioma (Gliomas) 11/2020 - 10/2003
9	Wounds and Injuries (Trauma) 10/2017 - 08/2003
4	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 10/2010
4	Diabetic Retinopathy (Retinopathy, Diabetic) 03/2016 - 04/2002
4	Breast Neoplasms (Breast Cancer) 02/2011 - 01/2005
3	Infections 01/2022 - 03/2010
3	Glioblastoma (Glioblastoma Multiforme) 10/2021 - 01/2005
3	Cataract (Cataracts) 10/2017 - 01/2002
3	Keratoconus 06/2008 - 10/2004
3	Retinal Neovascularization 05/2006 - 04/2002
2	Inflammation (Inflammations) 01/2022 - 01/2020
2	Edema (Dropsy) 10/2017 - 01/2002
2	Corneal Injuries 10/2017 - 11/2015
2	Type 2 Diabetes Mellitus (MODY) 10/2017 - 01/2017
2	Corneal Diseases (Corneal Disease) 03/2016 - 01/2013
2	Cicatrix (Scar) 11/2015 - 03/2010
2	Amyloid Plaque 09/2015 - 01/2011
2	Lung Neoplasms (Lung Cancer) 05/2015 - 04/2010
2	Neoplasm Metastasis (Metastasis) 04/2010 - 01/2005
2	Fuchs' Endothelial Dystrophy 10/2004 - 01/2002
1	Ulcer 01/2022
1	COVID-19 01/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2022
1	Amyloidosis 01/2020
1	Cognitive Dysfunction 01/2020
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2020
1	Blindness (Hysterical Blindness) 01/2019
1	Dermatitis 01/2018
1	Eye Diseases (Eye Disease) 01/2018
1	Latent Infection 01/2018
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2017
1	Macular Degeneration (Age-Related Maculopathy) 01/2017
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 03/2016
1	Parkinson Disease (Parkinson's Disease) 03/2016
1	Triple Negative Breast Neoplasms 12/2013
1	AIDS-Related Complex (ARC) 11/2013

Drug/Important Bio-Agent (IBA)

7	Retinaldehyde (Retinal)IBA 01/2020 - 04/2002
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
6	Pharmaceutical PreparationsIBA 01/2017 - 04/2010
5	poly(malic acid)IBA 12/2016 - 01/2006
5	Antisense OligonucleotidesIBA 02/2011 - 10/2003
4	Heptanol (1 Heptanol)IBA 12/2013 - 08/2003
4	laminin 8IBA 01/2006 - 10/2003
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 04/2002
3	Immunoconjugates (Immunoconjugate)IBA 11/2020 - 01/2019
3	ErbB Receptors (EGF Receptor)IBA 01/2020 - 12/2013
3	AntibodiesIBA 01/2019 - 05/2006
3	malic acid (malate)IBA 01/2019 - 10/2010
3	MicroRNAs (MicroRNA)IBA 01/2017 - 01/2013
3	MorpholinosIBA 02/2011 - 10/2003
3	Peptide Hydrolases (Proteases)FDA Link 06/2008 - 10/2005
3	Laminin (Merosin)IBA 01/2006 - 10/2003
2	PolymersIBA 10/2021 - 01/2019
2	epidermal growth factor receptor VIIIIBA 10/2021 - 12/2016
2	Glycoproteins (Glycoprotein)IBA 01/2018 - 03/2010
2	Messenger RNA (mRNA)IBA 02/2011 - 08/2009
2	Trastuzumab (Herceptin)FDA Link 02/2011 - 04/2010
2	Transferrin Receptors (Transferrin Receptor)IBA 02/2011 - 01/2006
2	Monoclonal AntibodiesIBA 10/2010 - 04/2010
2	polycefinIBA 04/2008 - 01/2006
2	Fibrillin-1IBA 09/2007 - 01/2002
2	TenascinIBA 09/2007 - 01/2002
2	Emodin (Archin)IBA 05/2006 - 12/2004
2	Casein Kinase II (Casein Kinase 2)IBA 05/2006 - 12/2004
2	Protein Isoforms (Isoforms)IBA 01/2006 - 01/2005
2	laminin 9IBA 01/2006 - 01/2005
2	Matrix Metalloproteinases (MMPs)IBA 10/2005 - 08/2003
1	NAD (NADH)IBA 01/2022
1	NeuropeptidesIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2020
1	ProteomeIBA 01/2020
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020
1	NestinIBA 01/2019
1	CTLA-4 AntigenIBA 01/2019
1	Biopolymers (Biopolymer)IBA 01/2019
1	Member 14 Tumor Necrosis Factor ReceptorsIBA 12/2018
1	Insulin (Novolin)FDA Link 10/2017
1	Biological ProductsIBA 01/2017
1	Nanoparticle Drug Delivery SystemIBA 01/2017
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2016
1	Ciliary Neurotrophic Factor (CNTF)IBA 03/2016
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 03/2016
1	Neuroprotective AgentsIBA 03/2016
1	CurcuminIBA 09/2015
1	Glatiramer Acetate (Copaxone)FDA Link 09/2015
1	Contrast MediaIBA 05/2015
1	gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetateIBA 05/2015
1	NanoconjugatesIBA 05/2015
1	Environmental Pollutants (Pollutants, Environmental)IBA 11/2013
1	Particulate MatterIBA 11/2013
1	3-hydroxycholest-7-ene-14-carbaldehydeIBA 01/2013

Therapy/Procedure

11	Therapeutics 01/2022 - 10/2003
3	Transplantation 10/2017 - 01/2013
2	Corneal Transplantation (Keratoplasty) 06/2008 - 01/2002
1	Refractive Surgical Procedures 10/2017
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2017
1	Immunotherapy 09/2015